COVID-19, Arrhythmic Risk and Inflammation: Mind the Gap!

Summary highlights that COVID-19 is burdened by a higher risk of arrhythmic events and should actively be considered when using off-label treatments with potential QTc prolongation effects (e.g. chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir).

Circulation